drugset / Trial / NCT01160731

Panobinostat, Etoposide, and Cisplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

NCT01160731

Phase 1 Withdrawn Cancer Trials Ireland
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Panobinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as etoposide and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving panobinostat together with etoposide and cisplatin may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of panobinostat when given together with etoposide and cisplatin as first-line therapy in treating patients with extensive-stage small cell lung cancer.

Timeline

Start
2009-11
Primary completion
2010-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Panobinostat Small molecule Intravenous
Background Cisplatin Other / unclassified Intravenous
Background Etoposide Small molecule Intravenous

Indications